Page 191 - Drug Class Review
P. 191

Drug Effectiveness Review Project











                          Drugs   Authors:  Rösler et al. 57    Country: Europe and North America  Novartis Pharma AG, Basle, Switzerland  To assess the effects of RIV on the core domains of AD  Setting: Multi-center (45 centers in North America and Europe)   placebo  rivastigmine 6-12 mg/d  rivastigmine 1-4 mg/d   N/A   6-12 mg/d   1-4 mg/d   26 weeks   26 weeks   26 weeks   239   243   243  50-85 years of age; not able to bear children; met DSM-IV criteria for Alzheimer’s type dementia; met  criteria for probable AD according to NINCDS/ADRDA; MMSE scores of 10-26; had a responsible  Severe and unstable cardiac disease; sev




                          Alzheimer     Year:  1999      Study design: RCT   Sample size: 725   caregiver






















             Final Report Update 1     Efficacy/Effectiveness  STUDY:      FUNDING:   RESEARCH OBJECTIVE:      DESIGN:           INTERVENTION:    Dose:     Duration:     Sample size:   INCLUSION:   EXCLUSION:   OTHER MEDICATIONS/  INTERVENTIONS ALLOWED:     Alzheimer's Drugs
   186   187   188   189   190   191   192   193   194   195   196